This article has been cited by the following publications. This list is generated based on data provided by Crossref.
2010. Current World Literature. Current Opinion in Rheumatology, Vol. 22, Issue. 6, p. 704.
Di Giacomo, Anna Maria Biagioli, Maurizio and Maio, Michele 2010. The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications. Seminars in Oncology, Vol. 37, Issue. 5, p. 499.
Boasberg, Peter Hamid, Omid and O’Day, Steven 2010. Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade. Seminars in Oncology, Vol. 37, Issue. 5, p. 440.
O'Regan, Kevin N. Jagannathan, Jyothipriya P. Ramaiya, Nikhil and Hodi, F. Stephen 2011. Radiologic Aspects of Immune-Related Tumor Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Ipilimumab Therapy. American Journal of Roentgenology, Vol. 197, Issue. 2, p. W241.
Bronstein, Yulia Ng, Chaan S. Hwu, Patrick and Hwu, Wen-Jen 2011. Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy. American Journal of Roentgenology, Vol. 197, Issue. 6, p. W992.
Specenier, Pol 2012. Ipilimumab in melanoma. Expert Review of Anticancer Therapy, Vol. 12, Issue. 12, p. 1511.
Bompaire, Flavie Mateus, Christine Taillia, Hervé De Greslan, Thierry Lahutte, Marion Sallansonnet-Froment, Magali Ouologuem, Madani Renard, Jean-Luc Gorochov, Guy Robert, Caroline and Ricard, Damien 2012. Severe meningo-radiculo-nevritis associated with ipilimumab. Investigational New Drugs, Vol. 30, Issue. 6, p. 2407.
Manousakis, Georgios Koch, James Sommerville, R. Brian El-Dokla, Ahmed Harms, Matthew B. Al-Lozi, Muhammad T. Schmidt, Robert E. and Pestronk, Alan 2013. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle & Nerve, Vol. 48, Issue. 3, p. 440.
Tarhini, Ahmad 2013. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. Scientifica, Vol. 2013, Issue. , p. 1.
Fecher, Leslie A. Agarwala, Sanjiv S. Hodi, F. Stephen and Weber, Jeffrey S. 2013. Ipilimumab and Its Toxicities: A Multidisciplinary Approach. The Oncologist, Vol. 18, Issue. 6, p. 733.
Callahan, Margaret K. Postow, Michael A. and Wolchok, Jedd D. 2013. Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clinics in Dermatology, Vol. 31, Issue. 2, p. 191.
Callahan, Margaret K. Postow, Michael A. and Wolchok, Jedd D. 2013. Cancer Immunotherapy. p. 287.
Voskens, Caroline J. Goldinger, Simone M. Loquai, Carmen Robert, Caroline Kaehler, Katharina C. Berking, Carola Bergmann, Tanja Bockmeyer, Clemens L. Eigentler, Thomas Fluck, Michael Garbe, Claus Gutzmer, Ralf Grabbe, Stephan Hauschild, Axel Hein, Rüdiger Hundorfean, Gheorghe Justich, Armin Keller, Ullrich Klein, Christina Mateus, Christine Mohr, Peter Paetzold, Sylvie Satzger, Imke Schadendorf, Dirk Schlaeppi, Marc Schuler, Gerold Schuler-Thurner, Beatrice Trefzer, Uwe Ulrich, Jens Vaubel, Julia von Moos, Roger Weder, Patrik Wilhelm, Tabea Göppner, Daniela Dummer, Reinhard Heinzerling, Lucie M. and Soyer, H. Peter 2013. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, Vol. 8, Issue. 1, p. e53745.
Delyon, J. Mateus, C. Lefeuvre, D. Lanoy, E. Zitvogel, L. Chaput, N. Roy, S. Eggermont, A.M.M. Routier, E. and Robert, C. 2013. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of Oncology, Vol. 24, Issue. 6, p. 1697.
Yust-Katz, Shlomit and Gilbert, Mark R. 2014. Abeloff's Clinical Oncology. p. 822.
Liao, B. Shroff, S. Kamiya-Matsuoka, C. and Tummala, S. 2014. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology, Vol. 16, Issue. 4, p. 589.
Bertrand, Anne Kostine, Marie Barnetche, Thomas Truchetet, Marie-Elise and Schaeverbeke, Thierry 2015. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine, Vol. 13, Issue. 1,
Howard, Stephanie A. Holler Krajewski, Katherine M. Jagannathan, Jyothi P. Braschi-Amirfarzan, Marta Tirumani, Sree H. Shinagare, Atul B. and Ramaiya, Nikhil H. 2016. A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. American Journal of Roentgenology, Vol. 207, Issue. 1, p. 4.
Specenier, Pol 2016. Ipilimumab in melanoma. Expert Review of Anticancer Therapy, Vol. 16, Issue. 8, p. 811.
Bilen, Mehmet Asim Subudhi, Sumit K. Gao, Jianjun Tannir, Nizar M. Tu, Shi-Ming and Sharma, Padmanee 2016. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer, Vol. 4, Issue. 1,